| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 07/14/2005 | US20050153876 Compositions of lipopeptide antibiotic derivatives and methods of use thereof |
| 07/14/2005 | US20050153875 Has an iron binding capacity of at least 1.0 mg-per gram of protein, is non-pyrogenic and is pathogen free; preparation by anion exchange chromatography |
| 07/14/2005 | US20050153874 Method of reducing serum proinsulin levels in type 2 diabetics |
| 07/14/2005 | US20050153873 Frequency assisted transdermal agent delivery method and system |
| 07/14/2005 | US20050153871 Administering N-hydroxy-N-(4-butyl-2-methylphenyl)-formamidine (HET0016) to increase or prevent a decrease in cerebral blood flow |
| 07/14/2005 | US20050153451 Intravascular delivery of non-viral nucleic acid |
| 07/14/2005 | US20050153416 Anticancer agents |
| 07/14/2005 | US20050153415 Lysin for use as tool in prevention of clostridial infection |
| 07/14/2005 | US20050153414 Regulator of G-protein signaling (RGS) polypeptide for use as tools in identifying modulators of cell signaling; antitumor agents; mimetics |
| 07/14/2005 | US20050153400 Human GIL-19/AE289 proteins and polynucleotides encoding same |
| 07/14/2005 | US20050153396 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 07/14/2005 | US20050153395 Unique integrin binding site in connective tissue growth factor (CTGF) |
| 07/14/2005 | US20050153391 Polypeptides capable of binding to G protein coupled receptors as well as DNA encoding for such polypeptides; receptor binding assays; drug screening; obesity; prolactin production inhibitors |
| 07/14/2005 | US20050153384 Identifying inhibitors of intracellular protein fibrillization |
| 07/14/2005 | US20050153376 Superantigens |
| 07/14/2005 | US20050153375 CEA/NCA-based differentiation cancer therapy |
| 07/14/2005 | US20050153374 Peptides and polypeptides derived from the submaxillary gland of the rat, corresponding polyclonal and monoclonal antibodies, corresponding hybridomas and uses of these products for diagnosis, for detection or therapeutic purposes |
| 07/14/2005 | US20050153373 Isolated from Bacillus substilis; multimeric polypeptide antigens; antibodies; solid phase synthesis; reverse transcription; kits; immunohistochemistry |
| 07/14/2005 | US20050153348 Using membrane protein expression pattern as diagnostic and prognostic tool in detection of breast, colon and lung tissue cell proliferative disorders |
| 07/14/2005 | US20050153340 Ribonuclease for use as tool in treatment and prevention of metabolic disorders |
| 07/14/2005 | US20050153335 Expression vector comprising nucleotide sequences coding membrane protein for use in identifying modulator for prevention and treatmment of cell proliferative, inflammatory and nervous system disorders |
| 07/14/2005 | US20050153334 Methods and materials relating to novel growth regulatory-like polypeptides and polynucleotides |
| 07/14/2005 | US20050153330 Novel DKR polypeptides |
| 07/14/2005 | US20050153327 Human ataxin-1-like polypeptide IMX97018 |
| 07/14/2005 | US20050153322 Administering to the mammal a polypeptide for stimulating gastrointestinal contractility in a mammal |
| 07/14/2005 | US20050153315 Nucleotide sequences coding polypeptide comprising methylarginase activities for use in identifying modulator for prevention and treatment of ischemia-reperfusion injuries, cancer, hypotension, multi-organ failure, arthritis, skin, inflammatory, cardiac and/or migraine disorders |
| 07/14/2005 | US20050153312 Nucleic acid compositions and methods of introducing nucleic acids into cells |
| 07/14/2005 | US20050153305 Novel proteins and nucleic acids encoding same |
| 07/14/2005 | US20050153295 Diagnostic and therapeutic use of human maguin proteins and nucleic acids for neurodegenerative diseases |
| 07/14/2005 | US20050153289 Method of analyzing gene expression |
| 07/14/2005 | US20050152985 The use of Colostrinin as a medicament, particularly in the treatment of chronic disorders of the central nervous system and the immune system. |
| 07/14/2005 | US20050152980 Pharmeutical microparticles |
| 07/14/2005 | US20050152979 comprising: a hydrophobic biologically active molecule or active agent; a polymeric carrier that renders the active agent soluble in water, and a reconstitution enhancer or enhancing agent; lyophilized |
| 07/14/2005 | US20050152966 For controlled release of lyophilized probiotic bacterium; compressed tablets |
| 07/14/2005 | US20050152952 Phaseolamin compositions and methods for using the same |
| 07/14/2005 | US20050152948 Soft tissue implants and anti-scarring agents |
| 07/14/2005 | US20050152947 Soft tissue implants and anti-scarring agents |
| 07/14/2005 | US20050152946 Implantable sensors and implantable pumps and anti-scarring agents |
| 07/14/2005 | US20050152945 Soft tissue implants and anti-scarring agents |
| 07/14/2005 | US20050152944 Breast, pectoral, chin, facial, lip, and nasal implants; inhibits angiogenesis and fibroblast migration; enzyme inhibitors |
| 07/14/2005 | US20050152941 Soft tissue implants and anti-scarring agents |
| 07/14/2005 | US20050152927 Allergenic proteins and peptides from Japanese cedar pollen |
| 07/14/2005 | US20050152926 For immunization and/or diagnosis; eg pneumonia, cardiovascular diseases, atherosclerosis, bronchitis |
| 07/14/2005 | US20050152925 Method for treating pain by peripheral administration of a neurotoxin |
| 07/14/2005 | US20050152924 Methods for treating sinus headache |
| 07/14/2005 | US20050152923 Methods for treating vascular disorders |
| 07/14/2005 | US20050152916 Antigen presenting system and methods for activation of T-cells |
| 07/14/2005 | US20050152909 Prostate stem cell antigen (PSCA) tumor antigen for use in diagnosis, prevention and treatment of prostate cancers |
| 07/14/2005 | US20050152905 by concurrent administration of prostaglandin inhibitors, modulator of neurotransmitters, interleukin inhibitors and tumor necrosis factor -lpha (TNF-alpha) inhibitors |
| 07/14/2005 | US20050152904 Novel P-selectin glycoprotein ligand (PSGL-1) binding protein and uses therefor |
| 07/14/2005 | US20050152897 Methods for inducing T cell tolerance to a tissue or organ graft |
| 07/14/2005 | US20050152893 Methods and materials for the inhibition of transplant rejection |
| 07/14/2005 | US20050152888 in a ubiquitin-independent manner comprising complexing proteasome-localizing agents with polypeptides and allowing degradation of the polypeptide |
| 07/14/2005 | US20050152887 Protonic formulation |
| 07/14/2005 | US20050152883 isolation of ligament cells, then culturing, recovering and implanting the cells into patients |
| 07/14/2005 | US20050152881 Composition of matrix suitable for implantation in humans defatting shredded allogenic human muscle tissues |
| 07/14/2005 | US20050152880 Matrix composition for human grafts/implants |
| 07/14/2005 | US20050152878 Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases |
| 07/14/2005 | US20050152877 CASH (CASPASE HOMOLOGUE) with death effector domain, modulators of the function of FAS receptors |
| 07/14/2005 | US20050152876 administering PTX3 to increase the amount or activity of Pentraxin 3 in the cumulous oophorus and/or the extracellular matrix of the cumulous oophorus |
| 07/14/2005 | US20050152875 administering interferon- beta (IFN- beta ) before organ grafting or surgery, for the prophylaxis of viral diseases such as hepatitis |
| 07/14/2005 | US20050152874 Unblocking immunization at a regional lymph node by: promoting differentiation and maturation of immature dendritic cells in a regional lymph node and; allowing presentation by resulting mature dendritic cells of antigen to T-cells |
| 07/14/2005 | US20050152872 Fusion constructs cotaining active sections of tnf ligands |
| 07/14/2005 | US20050152871 treating the subject in need with one or more chemokines and/or a DNA damaging agent inducing said chemokine(s); |
| 07/14/2005 | US20050152870 Pharmaceutical composition which improves in vivo gene transfer |
| 07/14/2005 | US20050152860 bone morphogenetic protein 4 (BMP-4) decreases melanin synthesis in melanocytes by decreasing the activity of tyrosinase |
| 07/14/2005 | US20050152853 Signal peptides, nucleic acid molecules and methods for treatment of caries |
| 07/14/2005 | US20050152848 covalently coupling insulin to one or more molecules of a non-naturally occurring hydrophilic polymer such as polyethylene glycol; antidiabetic agents |
| 07/14/2005 | US20050152836 Diagnostic markers and pharmacological targets in heart failure and related reagents and methods of use thereof |
| 07/14/2005 | DE10131145B4 Zusammensetzung zum zellspezifischen Transfer von Wirkstoffen Composition for cell-specific transfer of drugs |
| 07/14/2005 | CA2592504A1 Classification of cancer |
| 07/14/2005 | CA2552305A1 Use of macrolides for treating or preventing airflow obstruction |
| 07/14/2005 | CA2552155A1 Use of il-18 binding protein in inflammations |
| 07/14/2005 | CA2552150A1 Means for stimulation and activation of hair growth by il-15 |
| 07/14/2005 | CA2551916A1 Fc-erythropoietin fusion protein with improved pharmacokinetics |
| 07/14/2005 | CA2551915A1 Il-7 fusion proteins |
| 07/14/2005 | CA2551912A1 Methods of identifying immunoregulatory agents, immunoregulatory agents, and uses thereof |
| 07/14/2005 | CA2551510A1 Stable growth hormone liquid formulation |
| 07/14/2005 | CA2551259A1 A process for in vitro differentiation of neuronal stem cells or of cells derived from neuronal stem cells |
| 07/14/2005 | CA2550998A1 Use of fc receptor polymorphisms as diagnostics for treatment strategies for immune-response disorders |
| 07/14/2005 | CA2550872A1 Surface protection of exposed biological tissues |
| 07/14/2005 | CA2550833A1 Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent |
| 07/14/2005 | CA2550727A1 Treatment of coronary or peripheral ischemia |
| 07/14/2005 | CA2550455A1 Haemophilus influenzae type iv pili |
| 07/14/2005 | CA2550383A1 Methods and compositions for directing migration of neural progenitor cells |
| 07/14/2005 | CA2550344A1 18-membered nitrobenzyl-substituted and aminobenzyl-substituted cyclohexadepsipeptides for controlling endoparasites, and method for the production thereof |
| 07/14/2005 | CA2550301A1 Tissue regeneration method |
| 07/14/2005 | CA2548313A1 Methods and compositions for the prevention and treatment of inflammatory diseases or conditions |
| 07/14/2005 | CA2545722A1 Methods of treating asthma |
| 07/13/2005 | EP1553414A1 Methods for the diagnosis and treatment of metastatic prostate tumors |
| 07/13/2005 | EP1553182A2 Regulated genes and uses thereof |
| 07/13/2005 | EP1553178A1 Tumor-lysing virus growing selectively in tumor cells |
| 07/13/2005 | EP1553169A1 Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics |
| 07/13/2005 | EP1553168A2 Methods for selectively stimulating proliferation of T cells |
| 07/13/2005 | EP1552847A1 Inhibitors for continuous activation of calcineurin |
| 07/13/2005 | EP1552846A2 Use of heparinases to decrease inflammatory responses |
| 07/13/2005 | EP1552845A1 Preventives/remedies for cancer |
| 07/13/2005 | EP1552745A1 Therapeutic combinations of venous dilators and arterial dilators |
| 07/13/2005 | EP1552462A1 Methods of treating and preventing colitis involving il-13 and nk-t cells |
| 07/13/2005 | EP1552310A2 Diagnostic and therapeutic use of the nicotinamide mononucleotide adenylyltransferase 2 (nmnat-2) gene and protein for neurodegenerative diseases |